3 ASX biotech shares that have soared higher today

The ASX is home to a small but vibrant and growing biotechnology sector. Here we look at 3 ASX biotech shares that have soared higher today.

| More on:
Biotechnology graphics

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ASX is home to a small but vibrant and growing biotechnology sector. There are a number of providers that are making significant inroads on a global scale.

Here we examine 3 ASX biotech shares that have all seen strong share price rises today.

Zoono Group Ltd (ASX: ZNO)

The Zoono share price is up by a whopping 17% so far today. This strong rise is on the back of a solid rally in its share price last week.

From the beginning of last week, it has risen from $1.875 to its current price of $2.39. That's an impressive gain of 27%.

Zoono produces antibacterial skin and surface sanitisers. It has seen strong demand for its products since January. Its sanitisers haven been tested on the coronavirus and have achieved a 99.9% efficacy.

In a recent update, Zoono revealed invoiced sales of over NZ$11.0 million (unaudited) for the month of April.

The company has recently signed new distribution agreements in the UK and Europe. Zoono also reported strong sales in India and China, and has a new distributer in Hong Kong.

Paradigm Biopharmaceuticals Limited (ASX: PAR)

Paradigm focuses on the treatment of osteoarthritis. This is the most common joint disorder in the United States (US).

The ASX biotech share has risen by a significant 7% today (at the time of writing). This is on the back of strong share price rally since late April.

Paradigm's primary activity involves repurposing the drug pentosan polysylphate sodium (PPS) in injectable form through a drug called Zilosul. Zilosul has been registered in 4 of the 7 global pharmaceutical markets.

Paradigm has been conducting a trial into the use of Zilosul through the FDA's expanded access program.  Trials so far have reduced chronic pain by around 45%, which is very promising.

In early April, Paradigm conducted a $35 million institutional placement. It has reported it is in a strong cash position following this capital raise. The biotech company believes that this will fully fund its current work until the completion of its trials.

Opthea Ltd (ASX: OPT)

Opthea is a biotechnology company that develops new drugs for the treatment of eye diseases. Its share price is up by 11% today, which follows a strong rally in its share price since mid-March.

Opthea conducted a trial of its core drug OPT-302 last year. These trials indicated that it was capable of delivering significant vision improvement to patients. The company reported that the trials indicated the successful halting of the progression of the disease.

Opthea currently has a very strong balance sheet and it looks to be well-funded to carry it through its trials.

Motley Fool contributor Phil Harpur has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Share Gainers

These were the best-performing ASX 200 shares in March

These shares made their shareholders smile in March thanks to some very big gains.

Read more »

Businessman using a digital tablet with a graphical chart, symbolising the stock market.
Opinions

2 ASX shares I have been buying in 2024!

I’m a believer in the long-term outlook of these stocks.

Read more »

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why Burgundy Diamond Mines, Clarity Pharmaceuticals, EML, and Zip are sinking today

These ASX shares are ending the week in the red. But why?

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

a young boy dressed up in a business suit and tie has a cute grin and holds two fingers up.
Opinions

2 of my top ASX 200 shares to consider buying before April

I would happily exchange dollars for these two shares right now.

Read more »